MiNK Therapeutics Reports $2.9 Million Net Loss and Improved Cash Position in Latest 10-Q

MiNK Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $2.9 million for the third quarter, compared to a loss of $1.8 million in the same period last year. For the nine months ending September 30, 2025, the total net loss reached $9.9 million, up from $8.3 million in the prior year. Operating expenses increased, with research and development costs rising to $1.1 million for the quarter, a 111% increase from $540,638 in Q3 2024, primarily due to the absence of a prior year gain from liability forgiveness. General and administrative expenses also saw a 59% increase, totaling $1.8 million, attributed to higher professional fees.

The company’s financial position improved significantly, with cash and cash equivalents rising to $14.3 million as of September 30, 2025, compared to $4.6 million at the end of 2024. This increase was bolstered by net proceeds of approximately $13.1 million from the sale of common stock under an At Market Issuance Sales Agreement. Total assets reached $15 million, up from $5.7 million at the end of the previous fiscal year. However, MiNK continues to face challenges, with an accumulated deficit of $154.1 million and substantial liabilities, including a related party note of $5.7 million.

Strategically, MiNK has made notable advancements in its clinical programs, particularly with its lead product candidate, agenT-797, which is undergoing trials for various cancers and viral acute respiratory distress syndrome (ARDS). The company has established in-house manufacturing capabilities, enabling it to produce over 5,000 doses annually. Recent clinical trials have shown promising results, including durable responses in patients with advanced cancers. Additionally, MiNK is advancing next-generation engineered iNKT programs and has entered into a collaboration with ImmunoScape to develop T-cell receptor therapies.

Operationally, MiNK's workforce has seen fluctuations, with a decrease in headcount contributing to reduced personnel costs. The company is actively seeking additional funding sources, including strategic partnerships and potential equity or debt financing, to support its ongoing research and development efforts. Despite the positive cash position, management has indicated that substantial doubt exists regarding the company's ability to continue as a going concern for the next year, emphasizing the need for continued financial support and successful clinical outcomes to drive future growth.